Searched for
BBV154
Covid-19: Bharat Bio's nasal vaccine iNCOVACC set to cost Rs 325 at government hospitals, Rs 800 otherwiseThe vaccine, iNCOVACC (BBV154), is available on CoWin, and priced at Rs 800 for private markets and Rs 325 for supplies to the Centre and s...- Bharat Biotech's intranasal Covid vaccine approved, to be available on CO-WIN from FridayBharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry for inclusion in the vaccination programme as a bo...
- Easy to use, effective & economical: Nasal Covid vaccines to be a game-changer, say scientistsResearchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people.
- Easy to use, more effective and cheap, nasal Covid vaccines can be game changer: scientistsEarlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world's first intranasal COVID-19 vaccine, has received approva...
- Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age groupiNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candid...
- BBV154: What you need to know about Bharat Biotech's nasal Covid vaccineIt may produce local antibodies in the upper respiratory tract - which could provide the potential to reduce infection and transmission.
- Bharat Biotech seeks nod for intranasal Covid vaccineAccording to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...
- Submitted data for approval of intranasal vaccine to drug regulator: Bharat BiotechAccording to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...
- Bharat Biotech expects regulator's nod for intranasal COVID-19 vaccine in August"We will be applying for licenses and (they) should come. If everything goes well, we know by next month (August). You (people) would rathe...
- NTAGI may soon review efficacy data of India's first intranasal Covid vaccineThe date of the meeting is yet to be fixed. India's drug controller had in January this year given permission to Bharat Biotech to conduct ...
- Data required for suggesting mixing of COVID-19 vaccine:GovtThe Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore to conduct phase-I...
- Bharat Biotech gets nod for nasal Covid-19 vaccine's phase-3 clinical trials"Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce/stop transmission," the company said in a stat...
- DCGI allows Bharat Biotech to conduct phase-3 trials for Covid's intranasal booster doseThe trials of the Intranasal vaccine will take place at nine different sites of the country.
- Bharat Biotech seeks nod for phase-3 trials of intranasal COVID-19 vaccine as booster doseAn intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transm...
- Bharat Bio hopes to soon submit trial data for intranasal vaccine"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 part...
- AIIMS Delhi to conduct Phase 2 of Bharat Biotech's nasal vaccine trialsBharat Biotech has come out with non-invasive vaccine, which is in the second phase of its trials. The second phase of the trial will be co...
- Bharat Biotech gets nod for Phase 2/3 trials of intranasal Covid vaccineBBV154 is the first intranasal Covid-19 vaccine to undergo human trials in India. It has now received approval to conduct Phase 2 randomise...
- Bharat Biotech's Covid nasal vaccine gets regulator's nod for holding phase 2 clinical trialEarly stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be wel...
- Intranasal COVID vaccine candidate in early clinical stage of development in India: GovtMost vaccines are administered by injection through intramuscular or subcutaneous route.
- Expert panel recommends permission for phase 1 clinical trial of Bharat Biotech's nasal vaccine"Based on the safety and immunogenicity data of the phase 1 clinical trial, the company would be given permission for conducting phase 2 cl...
Load More
